Show simple item record

dc.contributor.authorCesne, ALen_US
dc.contributor.authorBauer, Sen_US
dc.contributor.authorDemetri, GDen_US
dc.contributor.authorHan, Gen_US
dc.contributor.authorDezzani, Len_US
dc.contributor.authorAhmad, Qen_US
dc.contributor.authorBlay, J-Yen_US
dc.contributor.authorJudson, Ien_US
dc.contributor.authorSchöffski, Pen_US
dc.contributor.authorAglietta, Men_US
dc.contributor.authorHohenberger, Pen_US
dc.contributor.authorGelderblom, Hen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2019-09-04T10:27:00Z
dc.date.issued2019-08-13en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/31409302en_US
dc.identifier10.1186/s12885-019-5988-3en_US
dc.identifier.citationBMC Cancer, 2019, 19 (1), pp. 794 - ?en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3330
dc.identifier.eissn1471-2407en_US
dc.identifier.doi10.1186/s12885-019-5988-3en_US
dc.description.abstractBACKGROUND: PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships between patient characteristics, prior lines of therapy, dose intensity, and dose modifications on safety and efficacy of pazopanib in aSTS. METHODS: PALETTE compared pazopanib with placebo in patients with aSTS (age ≥ 18 years) whose disease had progressed during or following prior chemotherapy. In these subgroup analyses, median progression-free survival (mPFS) among patients receiving pazopanib was the efficacy outcome of interest. Adverse events (AEs) were also compared within subgroups. All analyses were descriptive and exploratory. RESULTS: A total of 246 patients received pazopanib in the PALETTE study. The mPFS was longer in patients who had only 1 prior line versus 2+ prior lines of therapy (24.7 vs 18.9 weeks, respectively); AE rates were similar regardless of number of prior lines of therapy. The mPFS was similar in patients aged < 65 and ≥ 65 y (20.0 and 20.1 weeks, respectively). Although AEs leading to study discontinuation were higher in older patients (≥65 y, 30%; < 65 y, 17%), rates of dose reductions, dose interruptions, and serious AEs were similar between the 2 age groups. No reduction in mPFS was noted in patients requiring dose reductions or dose interruptions to manage toxicities. CONCLUSIONS: Longer mPFS was observed in patients receiving pazopanib following only 1 line of therapy. Additionally, mPFS with pazopanib was maintained regardless of patient age or dose modifications used to manage toxicity. TRIAL REGISTRATION: NCT00753688 , first posted September 16, 2008 (registered prospectively).en_US
dc.format.extent794 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectAdvanced soft tissue sarcomaen_US
dc.subjectPALETTE subgroup analysisen_US
dc.subjectPazopaniben_US
dc.subjectProgression-free survivalen_US
dc.titleSafety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.en_US
dc.typeJournal Article
dcterms.dateAccepted2019-07-29en_US
rioxxterms.versionofrecord10.1186/s12885-019-5988-3en_US
rioxxterms.licenseref.startdate2019-08-13en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBMC Canceren_US
pubs.issue1en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.publication-statusPublished onlineen_US
pubs.volume19en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamSarcoma Clinical Trialsen_US
dc.contributor.icrauthorJudson, Ianen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record